Sign inJoin waitlistJoin the waitlist

Eric Padron

Assoc Professor, Department of Oncologic Sciences · University of South Florida Morsani College of Medicine

Credentials: · · ·

History

H. Lee Moffitt Cancer Center and Research Institute
2009–2011
Internal Medicine
University of Florida
2006–2009
Univ of Florida Coll of Med
2002–2006

Research

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Review · Leukemia · 2022 · 3,530 citations
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Nature Genetics · 2020 · 651 citations
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Nature Medicine · 2018 · 455 citations

RK
Rami Komrokji
175 papers
DS
David Sallman
127 papers · 13 as a fellow
JL
Jeffrey Lancet
109 papers
AL
Alan List
88 papers
AK
Andrew Kuykendall
55 papers · 6 as a fellow
OC
Onyee Chan
51 papers · 1 as a fellow
KS
Kendra Sweet
50 papers
Mrinal Patnaik
43 papers
LZ
Ling Zhang
42 papers
Mikkael Sekeres
39 papers
AD
Amy DeZern
31 papers
Guillermo Garcia-Manero
29 papers

Grants

The Impact of Inflammation on HSPC Composition and Disease Progression in Chronic Myelomonocytic Leukemia
National Cancer Institute · R01
Contact PI · $2.2M · h. Lee Moffitt Cancer Ctr & Res Inst
2023–2028
Developing and Credentialing Patient-Derived Xenograft Models to Advance Therapeutic Approaches for Chronic Myelomonocytic Leukemia
National Cancer Institute · R37
Contact PI · $3.4M · h. Lee Moffitt Cancer Ctr & Res Inst
2019–2027
MALAT1 Depletion as a Therapeutic Strategy in Chronic Myelomonocytic Leukemia (CMML)
National Cancer Institute · R21
Contact PI · $405.9K · h. Lee Moffitt Cancer Ctr & Res Inst
2018–2019

Clinical trials

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Principal investigator · Active not recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2019–2027
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Principal investigator · Completed · Phase 1, Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2013–2022
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Sub-investigator · Recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2024–2027
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Sub-investigator · Recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2024–2028